Based on the ABVC Biopharma Inc stock forecast from 0 analysts, the average analyst target price for ABVC Biopharma Inc is not available over the next 12 months. ABVC Biopharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ABVC Biopharma Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, ABVC Biopharma Inc’s stock price was USD 0.52. ABVC Biopharma Inc’s stock price has changed by +3.76% over the past week, -7.65% over the past month and -52.79% over the last year.
No recent analyst target price found for ABVC Biopharma Inc
No recent average analyst rating found for ABVC Biopharma Inc
Company Overview ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation. Read Less
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast canc...Read More
Frequently Asked Questions About ABVC Biopharma Inc (ABVC) Stock
Stock Target Advisor's fundamental analysis for ABVC Biopharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ABVC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ABVC's stock to indicate what its average analyst target is.
ABVC stock's Price/Earning ratio is 0.01.
Our analysis grades ABVC stock's Price / Earning ratio at A-. This means that ABVC stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABVC may be undervalued for its sector.
The last closing price of ABVC's stock was USD 0.52.
The most recent market capitalization for ABVC is USD 6.18M.
Unfortunately we do not have enough analyst data on ABVC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ABVC Biopharma Inc's stock.
As per our most recent records ABVC Biopharma Inc has 16 Employees.
ABVC Biopharma Inc's registered address is 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538.
You can get more information about it from ABVC Biopharma Inc's website at https://www.abvcpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About ABVC Biopharma Inc (ABVC) Stock
Stock Target Advisor's fundamental analysis for ABVC Biopharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ABVC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ABVC's stock to indicate what its average analyst target is.
ABVC stock's Price/Earning ratio is 0.01.
Our analysis grades ABVC stock's Price / Earning ratio at A-. This means that ABVC stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABVC may be undervalued for its sector.
The last closing price of ABVC's stock was USD 0.52.
The most recent market capitalization for ABVC is USD 6.18M.
Unfortunately we do not have enough analyst data on ABVC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ABVC Biopharma Inc's stock.
As per our most recent records ABVC Biopharma Inc has 16 Employees.
ABVC Biopharma Inc's registered address is 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538.
You can get more information about it from ABVC Biopharma Inc's website at https://www.abvcpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABVC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
